Levetiracetam Tablet, Film Coated
Product Images NDC 63629-7516

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 63629-7516). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 2: Responder Rate (≥50% Reduction From Baseline) In Study 2: Period A (F7b86151 8fdf 4bb8 8cd6 E6e24786df64 02)

A formula displaying the calculation for creatinine clearance (CLcr) in mL/min, showing variables for age, weight, serum creatinine, and a factor for female patients. This formula is likely part of pharmacokinetic or dosing information related to Levetiracetam tablets, film coated, 1000 mg, from Bryant Ranch Prepack.*

FDA Label Image

Figure 3: Responder Rate (≥50% Reduction From Baseline) In Study 3 (F7b86151 8fdf 4bb8 8cd6 E6e24786df64 03)

A mathematical formula illustrating how to calculate creatinine clearance normalized to body surface area, showing the relationship between measured creatinine clearance, body surface area, and a constant factor of 1.73 m².*

FDA Label Image

Levetiracetam Structural Formula (F7b86151 8fdf 4bb8 8cd6 E6e24786df64 04)

Chemical structure of Levetiracetam, showing the molecular arrangement including a pyrrolidone ring with ethyl and amide substituents.*

FDA Label Image

Figure 1: Responder Rate (greater Than Or Equal To 50% Reduction From Baseline) In Study 1 (F7b86151 8fdf 4bb8 8cd6 E6e24786df64 05)

A bar chart titled 'Responder Rate (>50% Reduction From Baseline) In Study 1' showing the percentage of patients responding to treatment. It compares three groups: Placebo with 7.4%, Levetiracetam 1000 mg/day with 37.1%, and Levetiracetam 3000 mg/day with 39.6%. The chart notes statistical significance versus placebo for the Levetiracetam groups.*

FDA Label Image

Figure 3: Responder Rate (≥50% Reduction From Baseline) In Study 3 (F7b86151 8fdf 4bb8 8cd6 E6e24786df64 06)

Bar graph showing responder rates (≥50% reduction from baseline) in Study 2, Period A, comparing placebo, Levetiracetam 1000 mg/day, and Levetiracetam 2000 mg/day. The y-axis represents the percentage of patients, with rates of 6.3%, 20.8%, and 35.2% respectively, highlighting statistically significant improvements versus placebo for both Levetiracetam doses.*

FDA Label Image

Figure 3: Responder Rate (greater Than Or Equal To 50% Reduction From Baseline) In Study 3 (F7b86151 8fdf 4bb8 8cd6 E6e24786df64 07)

A bar chart titled 'Responder Rate (≥50% Reduction From Baseline) In Study 3' comparing the percentage of patients responding to placebo (14.4%) versus Levetiracetam 3000 mg/day (39.4%). The vertical axis represents the percentage of patients, with Levetiracetam showing a statistically significant higher response rate than placebo.*

FDA Label Image

Figure 4: Responder Rate (greater Than Or Equal To 50% Reduction From Baseline) (F7b86151 8fdf 4bb8 8cd6 E6e24786df64 08)

Bar graph showing responder rates (≥ 50% reduction from baseline) in Study 4 comparing Placebo (19.6% of patients, N=97) and Levetiracetam (44.6% of patients, N=101). A statistical significance indicator is shown for Levetiracetam versus placebo.*

FDA Label Image

Figure 5 (F7b86151 8fdf 4bb8 8cd6 E6e24786df64 09)

A bar graph comparing the percentage of patients for placebo and Levetiracetam groups. The placebo group (N=51) shows about 19.6% of patients, while the Levetiracetam group (N=58) shows about 43.1%. An asterisk indicates a statistically significant difference versus placebo.*

FDA Label Image

Figure 6: Responder Rate (greater Than Or Equal To 50% Reduction From Baseline) In Pgtc Seizure Frequency Per Week (F7b86151 8fdf 4bb8 8cd6 E6e24786df64 10)

A bar chart titled 'Responder Rate (≥50% Reduction from Baseline) in PGTC Seizure Frequency per Week in Study 7' showing the percentage of patients responding for placebo (45.2%, N=84) and Levetiracetam (72.2%, N=79). The chart indicates a statistically significant difference favoring Levetiracetam over placebo.*

FDA Label Image

Image 01

FDA Label Image

Label Image (Lbl636297516)

Label for Levetiracetam 1000 mg tablet, film coated, packaged by Bryant Ranch Prepack. The label compares the product to Keppra 1000 mg tablet from Zhejiang Huahai Pharma Co Ltd. It includes storage instructions at room temperature 20°-25°C and a caution to keep drugs out of children's reach. The package contains 30 tablets and displays the NDC 63629-7516.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.